Juniaum

Abstract

Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study.

Shelef A1, Barak Y1, Berger U2, Paleacu D1, Tadger S1, Plopsky I1, Baruch Y1.

Author information

1Abarbanel Mental Health Center, Bat-Yam, Israel and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

2Department of Psychology, Bar-Ilan University, Ramat-Gan, Israel.

Abstract

BACKGROUND:

Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD).

OBJECTIVE:

To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD).

METHODS:

Eleven AD patients were recruited to an open label, 4 weeks, prospective trial.

RESULTS:

Ten patients completed the trial. Significant reduction in CGI severity score (6.5 to 5.7; p <  0.01) and NPI score were recorded (44.4 to 12.8; p <  0.01). NPI domains of significant decrease were: Delusions, agitation/aggression, irritability, apathy, and sleep and caregiver distress.

CONCLUSION:

Adding MCO to AD patients' pharmacotherapy is safe and a promising treatment option.

KEYWORDS:

Alzheimer’s disease; behavioral and psychological symptoms of dementia; cannabis; tetrahydrocannabinol

PMID:

26757043

[PubMed - as supplied by publisher]

Fonte:http://www.ncbi.nlm.nih.gov/pubmed/26757043#Safety%20and%20Efficacy%20of%20Medical%20Cannabis%20Oil%20for%20Behavioral%20and%20Psychological%20Symptoms%20of%20Dementia:%20An-Open%20Label,%20Add-On,%20Pilot%20Study.